Immunotherapy before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has not been treated before, confirmed by a biopsy or other tissue test.
- Your doctor believes you are healthy enough for surgery to remove the tumor.
- You are willing and able to follow the study schedule and use birth control if needed.
- Your blood counts and organ function are within certain limits (e.g., adequate white blood cells, hemoglobin, platelets, and kidney/liver function).
- You do not have serious health issues like uncontrolled heart disease, diabetes, or active infections, and have not had other cancers recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests whether giving an immunotherapy drug (atezolizumab) before liver surgery can help your immune system fight liver cancer more effectively. You would receive the drug before your planned surgery, and the study will compare your outcomes with those who have surgery alone.
Hear when a new Hepatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.